3-[5-(azetidine-1-carbonyl)pyrazin-2-yl]oxy-5-[(2S)-1-methoxypropan-2-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide (BioDeep_00000837915)
代谢物信息卡片
化学式: C24H26N6O5 (478.1964586)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CN=C(C=N1)NC(=O)C2=CC(=CC(=C2)OC(C)COC)OC3=NC=C(N=C3)C(=O)N4CCC4
InChI: InChI=1S/C24H26N6O5/c1-15-10-27-21(12-25-15)29-23(31)17-7-18(34-16(2)14-33-3)9-19(8-17)35-22-13-26-20(11-28-22)24(32)30-5-4-6-30/h7-13,16H,4-6,14H2,1-3H3,(H,27,29,31)/t16-/m0/s1
描述信息
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Kieran McCafferty, Zoe Hollowood, Michelle Allen, Donna Lockhart, Jamie Chorlton, John Martin. ARCADIA study protocol: a phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with diabetes hospitalised with suspected or confirmed COVID-19.
BMJ open.
2021 12; 11(12):e049650. doi:
10.1136/bmjopen-2021-049650. [PMID: 34853102] - A J Krentz, L Morrow, M Petersson, E Norjavaara, M Hompesch. Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
Diabetes, obesity & metabolism.
2014 Nov; 16(11):1096-101. doi:
10.1111/dom.12323. [PMID: 24909093] - Terri Mitchard, Jane Stewart. The novel use of a heterozygous knockout mouse for embryofetal development assessment of a glucokinase activator.
Birth defects research. Part B, Developmental and reproductive toxicology.
2014 Apr; 101(2):152-61. doi:
10.1002/bdrb.21102. [PMID: 24753370] - D J Baker, G P Wilkinson, A M Atkinson, H B Jones, M Coghlan, A D Charles, B Leighton. Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.
British journal of pharmacology.
2014 Apr; 171(7):1642-54. doi:
10.1111/bph.12504. [PMID: 24772484] - A Kiyosue, N Hayashi, H Komori, M Leonsson-Zachrisson, E Johnsson. Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus.
Diabetes, obesity & metabolism.
2013 Oct; 15(10):923-30. doi:
10.1111/dom.12100. [PMID: 23522182] - L A Morrow, M Leonsson-Zachrisson, H Ericsson, M Wollbratt, M Knutsson, M Hompesch, E Norjavaara. Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.
Diabetes, obesity & metabolism.
2012 Dec; 14(12):1114-22. doi:
10.1111/j.1463-1326.2012.01661.x. [PMID: 22775976] - Ensio Norjavaara, Hans Ericsson, Folke Sjöberg, Maria Leonsson-Zachrisson, Mikaela Sjöstrand, Linda A Morrow, Marcus Hompesch. Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males.
The Journal of clinical endocrinology and metabolism.
2012 Sep; 97(9):3319-25. doi:
10.1210/jc.2012-1496. [PMID: 22723318]